Besides the pro-proliferation effect, ISO is a novel antagonist of PPAR-γ that inhibits adipocyte differentiation induced by the PPAR-γ agonist rosiglitazone, thereby obstructing obesity development and alleviating hepatic steatosis caused by high-fat diet and leptin deficiency [27]. Here, PPARG is linked to obesity disorder.